(Las Vegas, Nevada, United States) “Hemophilia A Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia A Market.
The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hemophilia A Pipeline Report:
- Hemophilia A companies working in the treatment market are Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others, are developing therapies for the Hemophilia A treatment
- Emerging Hemophilia A therapies such as – Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others are expected to have a significant impact on the Hemophilia A market in the coming years.
- In September 2022, Giroctocogene fitelparvovec is an investigational gene therapy for people with moderately to severely severe haemophilia A, according to a recent announcement from Pfizer and Sangamo Therapeutics. A crucial readout is predicted for the first half of 2024, and all trial sites are scheduled to be operational by the end of 2022.
- In June 2022, The second cohort of its Phase I/II B-LIEVE dose confirmation trial of FLT180a in patients with haemophilia B has started receiving doses, according to a release from Freeline Therapeutics Holdings
- In May 2022, The FDA has approved the biologics licence application (BLA) filed for etranacogene dezaparvovec for priority review, according to a statement from uniQure. For drugs that, if approved, could significantly improve the safety or efficacy of the treatment, diagnosis, or prevention of serious illnesses when compared to standard applications, a BLA is given priority evaluation
- In March 2022, ASC618 was given Fast Track designation by the Food and Drug Administration (FDA) for the treatment of haemophilia A.
- In November 2021, The pivotal phase III AFFINE study with giroctocogene fitelparvovec (SB-525 or PF07055480) and the Pfizer/Sangamo haemophilia A gene therapy programme have been placed on clinical hold pending FDA assessment of a proposed protocol revision
Hemophilia A Overview
A genetic bleeding illness termed haemophilia A, often called classical haemophilia, is brought on by low amounts of a bloodprotein called factor VIII. Those who have haemophilia A will bleed more than usual following an operation, dental procedure, or other trauma. This condition might be mild, moderate, or severe. In extreme situations, there may be no injury or perhaps a minor injury followed by massive bleeding.
Get a Free Sample PDF Report to know more about Hemophilia A Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020
Emerging Hemophilia A Drugs Under Different Phases of Clinical Development Include:
- Research program: Gene Therapies Generation Bio
- P-FVIII-101: Poseida Therapeutics
- AGN-193408: Allergan
- OCTA101: Octapharma
- ET3 lentiviral gene therapy: Expression Therapeutics
- NXT007: Chugai Pharmaceutical
- ASC618: ASC Therapeutics
- SelectAte: Ascension
- STSP-0601: Staidson (Beijing) Biopharmaceuticals
- TQG 203: Chia Tai Tianqing Pharmaceutical Group
- Mim8: Novo Nordisk
- Giroctocogene fitelparvovec: Pfizer
Route of Administration
Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Small molecules
- Gene Therapies
- Bispecific antibodies
- Recombinant proteins
- Fusion Proteins
- Coagulants
- Blood coagulation factor replacements
Hemophilia A Pipeline Therapeutics Assessment
- Hemophilia A Assessment by Product Type
- Hemophilia A By Stage and Product Type
- Hemophilia A Assessment by Route of Administration
- Hemophilia A By Stage and Route of Administration
- Hemophilia A Assessment by Molecule Type
- Hemophilia A by Stage and Molecule Type
DelveInsight’s Hemophilia A Report covers around 40+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Hemophilia A product details are provided in the report. Download the Hemophilia A pipeline report to learn more about the emerging Hemophilia A therapies
Some of the key companies in the Hemophilia A Therapeutics Market include:
Key companies developing therapies for Hemophilia A are – Intellia tx, Amarna therapeutics, Expression Therapeutics, GC Pharma, Chameleon Biosciences, Pfizer, UBI Pharma, GeneVentiv, Chia Tai Tianqing Pharmaceutical Group, Bayer, ASC Therapeutics, Catalyst Biosciences, Staidson Beijing BioPharmaceuticals, Spark Therapeutics, CSL Behring, Sanofi, Novo Nordisk, Centessa Pharmaceuticals, OPKO Health, Freeline Therapeutics, Spark Therapeutics, Novo Nordisk, Asklepios BioPharmaceutical, Belief Biomed, ASC Therapeutics, uniQure, Sanofi, Bioverativ, and others.
Hemophilia A Pipeline Analysis:
The Hemophilia A pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
- Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market.
Download Sample PDF Report to know more about Hemophilia A drugs and therapies
Hemophilia A Pipeline Market Drivers
- Increasing number of hemophilic patients worldwide, increasing development of novel therapies, increasing diagnostic rate are some of the important factors that are fueling the Hemophilia A Market.
Hemophilia A Pipeline Market Barriers
- However, side effects associated with the plasma derived products, high cost of recombinant products and other factors are creating obstacles in the Hemophilia A Market growth.
Scope of Hemophilia A Pipeline Drug Insight
- Coverage: Global
- Key Hemophilia A Companies: Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others
- Key Hemophilia A Therapies: Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others
- Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
- Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers
Request for Sample PDF Report for Hemophilia A Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Hemophilia A Report Introduction |
|
2 |
Hemophilia A Executive Summary |
|
3 |
Hemophilia A Overview |
|
4 |
Hemophilia A- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Hemophilia A Pipeline Therapeutics |
|
6 |
Hemophilia A Late Stage Products (Phase II/III) |
|
7 |
Hemophilia A Mid Stage Products (Phase II) |
|
8 |
Hemophilia A Early Stage Products (Phase I) |
|
9 |
Hemophilia A Preclinical Stage Products |
|
10 |
Hemophilia A Therapeutics Assessment |
|
11 |
Hemophilia A Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Hemophilia A Key Companies |
|
14 |
Hemophilia A Key Products |
|
15 |
Hemophilia A Unmet Needs |
|
16 |
Hemophilia A Market Drivers and Barriers |
|
17 |
Hemophilia A Future Perspectives and Conclusion |
|
18 |
Hemophilia A Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services